Related Experiment Video
Updated: Feb 6, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Polyamine Biosynthetic Pathway as a Drug Target for Osteosarcoma Therapy
Rebecca R Weicht1,2, Chad R Schultz1, Dirk Geerts3
1Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, 400 Monroe Avenue, NW, Grand Rapids, MI 49503, USA. andre.bachmann@hc.msu.edu.
Abstract:
Osteosarcoma (OS) is the most common bone tumor in children. Polyamines (PAs) are ubiquitous cations involved in many cell processes including tumor development, invasion and metastasis. In other pediatric cancer models, inhibition of the PA biosynthesis pathway with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) results in decreased cell proliferation and differentiation. In OS, the PA pathway has not been evaluated. DFMO is an attractive, orally administered drug, is well tolerated, can be given for prolonged periods, and is already used in pediatric patients. Three OS cell lines were used to study the cellular effects of PA inhibition with DFMO: MG-63, U-2 OS and Saos-2. Effects on proliferation were analyzed by cell count, flow cytometry-based cell cycle analysis and RealTime-Glo™ MT Cell Viability assays. Intracellular PA levels were measured with high-performance liquid chromatography (HPLC). Western blot analysis was used to evaluate cell differentiation. DFMO exposure resulted in significantly decreased cell proliferation in all cell lines. After treatment, intracellular spermidine levels were drastically decreased. Cell cycle arrest at G₂/M was observed in U-2 OS and Saos-2. Cell differentiation was most prominent in MG-63 and U-2 OS as determined by increases in the terminal differentiation markers osteopontin and collagen 1a1. Cell proliferation continued to be suppressed for several days after removal of DFMO. Based on our findings, DFMO is a promising new adjunct to current osteosarcoma therapy in patients at high risk of relapse, such as those with poor necrosis at resection or those with metastatic or recurrent osteosarcoma. It is a well-tolerated oral drug that is currently in phase II clinical trials in pediatric neuroblastoma patients as a maintenance therapy. The same type of regimen may also improve outcomes in osteosarcoma patients in whom there have been essentially no medical advances in the last 30 years.
Insights
Alpha-difluoromethylornithine (DFMO) effectively inhibits polyamine synthesis, reducing osteosarcoma cell proliferation and promoting differentiation. This well-tolerated oral drug shows promise as an adjunct therapy for high-risk pediatric osteosarcoma patients.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Osteosarcoma (OS) is a common pediatric bone cancer with limited therapeutic advances.
- Polyamines (PAs) are crucial for tumor development, invasion, and metastasis.
- The polyamine pathway's role in OS remains unevaluated.
Purpose of the Study:
- To investigate the effects of polyamine inhibition using alpha-difluoromethylornithine (DFMO) on osteosarcoma cell lines.
- To assess DFMO's impact on cell proliferation, cell cycle, differentiation, and polyamine levels in OS.
- To evaluate DFMO as a potential adjunct therapy for osteosarcoma.
Main Methods:
- Utilized three human osteosarcoma cell lines (MG-63, U-2 OS, Saos-2).
- Assessed proliferation via cell counting, flow cytometry, and viability assays.
- Measured intracellular polyamine levels using HPLC and evaluated differentiation via Western blot.
Main Results:
- DFMO significantly decreased proliferation across all tested OS cell lines.
- Intracellular spermidine levels were markedly reduced post-treatment.
- Observed G₂/M cell cycle arrest in U-2 OS and Saos-2 cells.
- DFMO promoted cell differentiation, evidenced by increased osteopontin and collagen 1a1 expression.
Conclusions:
- DFMO effectively inhibits osteosarcoma cell proliferation and induces differentiation.
- DFMO demonstrates potential as a well-tolerated oral adjunct therapy for high-risk osteosarcoma patients.
- Further investigation of DFMO for osteosarcoma treatment is warranted, given the lack of recent therapeutic advancements.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Related Concept Videos
01:29Amino Acid Biosynthetic Pathways
01:28Drug Therapy
Antianxiety Medications
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...